Introduction: Pulmonary emphysema is a frequent comorbidity in lung cancer, but its role in tumor prognosis remains obscure. Our aim was to evaluate the impact of the regional emphysema score (RES) on a patient's overall survival, quality of life (QOL), and recovery of pulmonary function in stage I to II lung cancer.
Introduction
Chronic obstructive pulmonary disease (COPD) and lung cancer are leading causes of death worldwide. 1 Emphysema is the major component of COPD and has been demonstrated to confer a higher risk for lung cancer, independent of tobacco smoking and airflow obstruction. 2, 3 It is reported that more than half of patients with newly diagnosed lung cancer have emphysema, 4, 5 but the prognostic role of emphysema in lung cancer remains unclear and conflicting. [6] [7] [8] [9] Our previous experience indicates that the local risk for lung cancer was related to severity of regional emphysema 10 ;
however, the prognostic significance of regional emphysema has not been well characterized. This article investigates the impact of regional emphysema score (RES) on patients with early-stage NSCLC in terms of overall survival (OS), health-related quality of life (QOL), and postoperative recovery of pulmonary function.
Methods

Subject Recruitment
The study protocol was approved by the Mayo Clinic Institutional Review Board. Detailed procedures of patient enrollment, data collection, and follow-up have been described in previous publications. 11, 12 To ensure patients with at least 5-year follow-up appointments, the cohort of patients whose disease was diagnosed between 1997 and 2009 was considered; a total of 1073 patients met our study inclusion criteria: pathologically confirmed early-stage NSCLC (stage I-II), available standard-dose computed tomography (CT) scan before treatment, and provision of written informed consent.
Patient Evaluation
The details of patient preoperative evaluations have been reported in a previous work. 13 The diagnosis of COPD was determined by patient's medical record and/ or documented irreversible airflow limitation (ratio of postbronchodilator forced expiratory volume in 1 second to forced vital capacity [FEV 1 /FVC] < 70% 14 ). Perioperative mortality was defined as death during hospitalization or within 30 days of operation. 13 Postoperative complications included conditions such as atrial fibrillation, pneumonia, prolonged air leak (>7 days), and tracheostomy that occurred during hospitalization or within 30 days after operation. A composite variable, any postoperative complications, consisting of any complications recorded (including but not limited to the aforementioned) was generated for each individual patient. Pulmonary function tests (PFTs) were performed within half a year before lung cancer treatment and repeated within 2 years after pulmonary resection. The values of FEV 1 /FVC, percentage of FEV 1 (FEV 1 %), residual volume, total lung capacity, and diffusion capacity of lung for carbon monoxide were evaluated and expressed as the changes from preoperative to postoperative evaluation. QOL was assessed by using the Lung Cancer Symptom Scales 15 within 2 years after treatment, and each item was scored on a scale of 0 (worst) to 10 (best).
Emphysema Evaluation
Emphysema evaluation was based on a standard-dose CT scan before treatment. Patients with a low-dose CT scan only were excluded. The methods of radiological diagnosis and quantification of emphysema have been reported. 10, [16] [17] [18] In brief, the severity of emphysema was scored through direct interpretation by an experienced thoracic radiologist (S.J.S.) using computer-aided quantitative standard images that were generated with -950 Hounsfield units as the threshold for emphysema. The extent of emphysema was given for each of six lung zones: right and left lung and upper, middle (or lingula), and bilateral lower lobes. Individual RESs were derived from the emphysematous region and classified as follows: mild (5%), moderate (6%-24%) and severe (25%-60%). Patients were then divided into three groups according to the tumor location and treatment modality ( 
Statistical Analysis
Clinical data were compared using the chi-square test or Fisher's exact text (as appropriate) for categorical variables and the unpaired t test for continuous variables. Survival curves were generated by the Kaplan-Meier method and differences were assessed by the log-rank test. Cox proportional hazards models were used to evaluate the association between RES and OS after adjusting for the patient's demographics, tumor stage and treatment, and COPD status. The difference in QOL between groups was assessed by using the chi-square test, and a clinically important difference was defined as a greater than one point. A p value less than 0.05 was considered statistically significant. All statistical analyses were performed with SAS, version 9.3, software (SAS Institute Inc., Cary, NC).
Results
Baseline Clinical Features
In all groups, moderate and severe RESs were noted more frequently than mild RESs in patients who were former or current smokers and had smoked for more pack-years (p < 0.05). Coexistence of COPD was significantly more frequent in patients with a higher RES (p < 0.01). Of the 1000 patients receiving surgical resection Table 1 .
In surgically treated patients (group 1 and group 2), the preoperative PFT results are summarized in Supplementary Table 1 . As expected, with higher RESs, there was evidence of greater airflow obstruction, lower diffusion capacity, and more marked hyperinflation. Postoperative complications increased in both surgical groups as the RES increased (Table 2) . Postoperative pneumonia occurred more frequently in patients with a severe RES than in those with a mild to moderate RES in both groups (both p < 0.05). In group 1 (cancer in the emphysematous region), the incidence of prolonged air leak was twice as high in patients with a moderate RES and three times as high in patients with a severe RES than in patients with a mild RES (p < 0.01). Three patients died during the postoperative course, including two of pneumonia and one of acute renal failure; however, there was no significant association between the RES and perioperative mortality in either group.
Changes in Pulmonary Function
After surgery, 152 patients in group 1 (26.9%) and 122 in group 2 (28.0%) had a follow-up PFT at a mean of 13.4 ± 5.9 months after surgery (range 3.2-23.8 months). In general, some decline in lung function was noticed in both groups. In group 1 (cancer in the emphysematous region) there was a significantly greater decline in lung function (as measured by FEV 1 % and percentage of diffusion capacity of lung for carbon monoxide) in patients with a mild RES than in those with a moderate or severe RES; however, a significant improvement in FEV 1 /FVC was observed in patients with a moderate or severe RES. These associations were not evident in group 2 (cancer in the nonemphysematous region) ( Supplementary Fig. 1 ).
Posttreatment QOL
Within 2 years after treatment, 394 patients in group 1 (69.7%), 322 in group 2 (74.0%), and 54 in group 3 (74.0%) answered the QOL questionnaire. No striking difference in overall QOL was observed between different RESs in each group (Fig. 2) . On the specific symptom subscales, dyspnea scores were worse in patients with a severe RES in all groups (all p < 0.05 and difference >1 point). In group 3 (cancer with nonsurgical treatment), fatigue was worse in patients with a moderate or severe RES than in those with a mild RES, which was independent of nonsurgical treatment modalities (p ¼ 0.68).
OS
The respective 5-year OS rates in patients with mild, moderate, and severe RESs were 79.6%, 67.8%, and 63.8% in group 1; 74.1%, 55.8%, and 50.0% in group 2; and 24.3% and 22.2% in patients with mild and moderate to severe RESs in group 3. Kaplan-Meier survival analysis showed significant differences in OS among those with mild, moderate, and severe RESs in the surgical groups (both p < 0.01), but no significant difference between mild and moderate to severe RES in the nonsurgical group (p ¼ 0.90 [ Fig. 3 Comparisons between different emphysema scores in group 1 and group 2, p < 0.01.
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HR ¼ 2.04, 95% CI: 1.33-3.12). RES was not a prognostic factor in group 3 (Table 3 and Supplementary Table 2 ).
Discussion
Emphysema is a frequent coexisting disease in patients with lung cancer and increases postoperative pulmonary morbidities after lung resection. 9, 19 In this retrospective analysis, we found that the RES was an independent predictor of OS in early-stage NSCLC after surgery regardless of tumor location, and it was also associated with posttreatment dyspnea in those with a severe RES versus a mild or moderate RES. Lung function declined postoperatively in both surgical groups, with a significant increase in FEV 1 /FVC noted in those with a moderate or severe RES in group 1 (cancer in the emphysematous region).
To date, much attention has been focused on the difference in prognosis between lung cancer arising in emphysematous and nonemphysematous lungs. 7 Several studies 6, 8, 20 reported an association between the presence of emphysema and lung cancer mortality but other studies 9, 21, 22 did not support such association after controlling for patient age, sex, smoking history, and cancer stage. In these previous studies, quantification of emphysema was based on whole lung evaluation, without accounting for the regional distribution of emphysema. However, recent studies 4, 10 suggest that primary lung cancers arise more frequently in regional areas of worse emphysematous change. We therefore hypothesized that RES may have prognostic value in lung cancer.
The multivariate analysis demonstrated that higher RES was significantly associated with worse OS in surgically treated lung cancer, regardless of the tumor location and independent of smoking and COPD status. This finding was in line with previous studies in which emphysema was quantified according to whole lung evaluation. 4, 6, 8 Zulueta et al. revealed that patients with mild, moderate, and marked emphysema had a respective HR of death from lung cancer of 1.4, 1.8, and 3.2 as compared with those patients who were free of emphysema. 8 Oelsner et al. demonstrated an association between quantitatively assessed emphysema and lung Figure 3 . Kaplan-Meier curves for overall survival between different regional emphysema scores (RESs) in three groups: lung cancer in the emphysematous region with surgical resection (A); lung cancer in the nonemphysematous region with surgical resection (B); and lung cancer with nonsurgical treatment (C). There were significant differences in overall survival among patients with mild, moderate, and severe RESs in surgically treated lung cancer, regardless of tumor location (p < 0.01). This difference was insignificant between patients with mild RESs and those with moderate/severe RESs when lung cancer was treated nonsurgically (p ¼ 0.90).
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Regional Emphysema and Lung Cancer Outcomescancer mortality in which patients with worse emphysema had poorer outcomes. 6 Our results indicated that RES had an impact on OS similar to that of generalized emphysema, and that a systemic effect of RES might underlie the prognostic association. Possible systemic mechanisms for the effect of regional emphysematous change on lung cancer survival in this study cohort could include the tumor-promoting effect of neutrophilic inflammation, [23] [24] [25] enhanced angiogenesis secondary to chronic inflammation, 26 and upregulation of matrix metalloproteinase in emphysematous lungs. 7, 27 Upregulation of matrix metalloproteinase has been associated with lymphovascular tumor invasion and postoperative recurrence 27 and could potentially contribute to poorer outcomes with more severe RES.
Health-related QOL has been increasingly emphasized in lung cancer. 15 Previous studies found that patient comorbidities, such as COPD, did not affect QOL for patients with lung cancer 28, 29 ; however, the influence of emphysema is still uncertain. Our results showed that the overall QOL did not differ significantly between RES whereas dyspnea scores were worse in patients with a severe RES in all groups. Dyspnea has been reported to constitute a major component of symptom burden in patients with lung cancer. 30 Balduyck et al. found a significant correlation between comorbidity index and postoperative dyspnea. 31 Fatigue is a frequent symptom of inoperable lung cancer. 32 Our study found that fatigue was associated with RES in the nonsurgical group; however, these results are limited by the small number of patients.
Lung function is the main limiting factor when planning surgery for early-stage lung cancer. It has been recognized that lobectomy may lead to an improvement in postoperative ventilation capacity in patients with moderate to severe pulmonary emphysema. 33, 34 Our findings highlighted the predictive value of RES in postoperative recovery of pulmonary function. When tumor resection was performed in the emphysematous region (group 1), patients with a higher RES had less marked declines in FEV 1 % but greater reductions in residual volume, contributing to a "volume reduction effect" on FEV 1 /FVC (and a subsequent increase in FEV 1 /FVC). This finding concurred with those of Ueda et al., 35 who reported an association between emphysematous lung tissue in resected lung and volume reduction effect on postoperative FEV 1 /FVC. In contrast, when lung cancer occurred away from the emphysematous region (group 2), no obvious volume reduction effect was noted after surgical resection.
RES was significantly associated with postoperative pneumonia in both surgical groups. Prolonged air leak occurred more frequently in those patients with a severe RES, and a statistically significant difference was noted in group 1 (cancer in the emphysematous region) for a severe RES compared with a mild or moderate RES. Possible mechanisms include poorer postoperative healing owing to more fragile, emphysematous tissue after surgery. 36 The current study has several limitations. First, although our patient cohort was prospectively followed in the past decade, this study was retrospective and observational in nature; thus, the potential bias could not be completely eliminated even with rigorous statistical analysis. Second, follow-up by lung function was not conducted routinely in the postoperative course; rather, the PFT data were passively collected upon availability in medical records; only one-fourth of patients had follow-up of lung function. Third, preoperative QOL was unavailable, which limits the ability of the study to assess the effects of therapy (and RES) on posttreatment change. Lastly, the relatively small number of early-stage patients who received nonsurgical treatment in the present study limits interpretation of results for this group. Therefore, a larger-scale study is needed to confirm our results.
In conclusion, we explored the prognostic significance of regional emphysema severity in a retrospective cohort and found that RES was an independent predictor of OS in early-stage NSCLC after surgery regardless of tumor location and was associated with posttreatment QOL related to dyspnea and postoperative recovery of pulmonary function.
